Experience of sucroferric oxyhydroxide

Abstract

In this study, 21 dialysis patients who were administered sucroferric oxyhydroxide (SO) were examined. They were treated at Suzuki Clinic (Enjinkai Group) using a phosphate binder, but not iron. The phosphate binder was switched to SO at the same dose. The serum phosphorus level, the levels of iron metabolism markers, the frequency of side effects, and the serum fibroblast growth factor 23 (FGF23) level were measured before and 12 weeks after the switch and compared. The serum phosphorus levels of the 18 patients who were able to continuously take SO decreased significantly. Three patients stopped taking SO because of side effects (diarrhea, two patients ; loose stools, one patient). No significant changes in the levels of iron metabolism markers were seen after the switch. The change in the serum FGF23 level depended on the predialysis serum phosphorus level.